Skip to main content
ANGIODYNAMICS INC logo

ANGIODYNAMICS INC — Investor Relations & Filings

Ticker · ANGO ISIN · US03475V1017 LEI · 549300W3VKC5ZKMO8C28 US Manufacturing
Open in API
Filings indexed 1,054 across all filing types
Latest filing 2012-05-25 Capital/Financing Update
Country US United States of America
Listing US ANGO

About ANGIODYNAMICS INC

https://www.angiodynamics.com/

AngioDynamics Inc. is a medical technology company focused on developing, manufacturing, and selling innovative, minimally invasive devices. The company's core activities center on restoring healthy blood flow in the vascular system and expanding cancer treatment options. Its product portfolio serves healthcare professionals such as interventional radiologists, cardiologists, and surgeons. Key technology platforms include the Auryon System, an advanced peripheral atherectomy device; the AlphaVac System for mechanical thrombectomy; and the NanoKnife System for precise, non-thermal tumor ablation. AngioDynamics is dedicated to improving patient outcomes through technologies designed for vascular access, peripheral vascular disease, and oncology.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 21, 2012, by AngioDynamics, Inc. It details the completion of an acquisition of Navilyst, including the entry into a material definitive agreement (Stock Purchase Agreement), a Credit Agreement for financing, a Stockholders Agreement, and an Escrow Agreement. The document includes detailed descriptions of these agreements and the financing arrangements related to the acquisition. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other types of filings. Instead, it is a current report announcing significant corporate events and financing related to an acquisition. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. The document length (15,000 characters) and detailed content support this classification with high confidence.
2012-05-25 English
FORM 4
Director's Dealing
2012-05-23 English
SCHEDULE 13D
Major Shareholding Notification
2012-05-23 English
FORM 3
Director's Dealing
2012-05-23 English
FORM 3
Director's Dealing
2012-05-23 English
FORM 3
Director's Dealing
2012-05-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.